CLINICAL TRIALS PROFILE FOR MANGANESE CHLORIDE

« Back to Dashboard

All Clinical Trials for MANGANESE CHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03989310 ↗	An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer	Recruiting	Chinese PLA General Hospital	Phase 1/Phase 2	2019-03-01	The outcome of pancreatic cancer is extremely poor. NCCN guidelines recommend FOLFIRINOX or modified-FOLFIRINOX as the first-line chemotherapeutic regimen, but the response rate is unacceptably low. PD-1 blockade has been developed to a new class of cancer immunotherapy that could restore an adequate immunosurveillance against the neoplasm and enhance T-cell-mediated anticancer immune responses. Manganese has been confirmed to activate antigen-presenting cells and function as mucosal immunoadjuvants in pre-clinical studies. This one-arm, phase I/II study is designed to assess the safety and efficacy of Manganese primed combined therapy of anti-PD-1 antibody and chemotherapy.
NCT03989336 ↗	An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer	Recruiting	Chinese PLA General Hospital	Phase 1/Phase 2	2019-06-20	Ovarian cancer is the most lethal gynecological cancer and the 5th leading cause of cancer death in women. Platinum chemotherapy has been widely adopted as a standard treatment for advanced ovarian cancer, the response rates in patients with relapsed/refractory ovarian cancer is unacceptably low. PD-1 blockade has been developed to a new class of cancer immunotherapy that could restore an adequate immunosurveillance against the neoplasm and enhance T-cell-mediated anticancer immune responses. Manganese has been confirmed to activate antigen-presenting cells and function as mucosal immunoadjuvants in pre-clinical studies. This two-arm, phase I/II study is designed to assess the safety and efficacy of combined therapy of anti-PD-1 antibody and chemotherapy with or without Manganese priming.
NCT03991559 ↗	A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas	Unknown status	Chinese PLA General Hospital	Phase 1	2018-11-01	Identification of T cell inhibitory signals, including PD-1/PD-L1, has prompted the development of a new class of cancer immunotherapy that could restore an adequate immunosurveillance against the neoplasm and enhance T-cell-mediated anticancer immune responses. However, elimination of cancer by T cells is only one step in the Cancer-Immunity Cycle, which enable providing several therapeutic targets and tailoring of combinations of immune therapies. Manganese has been confirmed to activate antigen-presenting cells and function as mucosal immunoadjuvants in pre-clinical studies. This study is a first-in-man, Phase I, 3 + 3 dose escalation study of a combined regimen of Manganese and anti-PD-1 antibody with or without chemotherapies in subjects with unresectable/ metastatic solid tumors or lymphomas. This study is designed to assess the safety, tolerability, pharmacokinetic profile (PK profile), mode of delivery and Recommended Phase 2 Dose (RP2D) of this regimen.
NCT04004234 ↗	A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC	Unknown status	Chinese PLA General Hospital	Phase 1/Phase 2	2019-03-01	Biliary tract cancer (BTC) is a rare heterogeneous collection of malignancies arising within the biliary tract, characterized by innate chemoresistance and abysmal prognosis. PD-1 blockade has been developed to a new class of cancer immunotherapy that could restore an adequate immunosurveillance against the neoplasm and enhance T-cell-mediated anticancer immune responses. Manganese has been confirmed to activate antigen-presenting cells and function as mucosal immunoadjuvants in pre-clinical studies. This open-label, phase I/II study is designed to assess the safety and efficacy of Manganese primed combined therapy of anti-PD-1 antibody and gemcitabine/cisplatin chemotherapy.
NCT04119843 ↗	Safety and Diagnostic Efficacy of Mangoral in Participants With Focal Liver Lesions and Reduced Kidney Function	Recruiting	Ascelia Pharma AB	Phase 3	2020-02-19	The overall objective of this study is to evaluate the safety and diagnostic efficacy of Mangoral in liver MRI in participants with known or suspected focal liver lesions and severe renal impairment. The diagnostic efficacy of Mangoral will be assessed in terms of visualization of detected focal liver lesions in combined MRI (CMRI: combined Mangoral-enhanced and unenhanced MRI) compared to unenhanced MRI.
NCT04873440 ↗	An Open-label, Phase I/II Study of Manganese Plus Radiotherapy in Patients With Metastatic Solid Tumors or Lymphoma	Recruiting	Chinese PLA General Hospital	Phase 1/Phase 2	2021-05-06	Radiotherapy is a regular care for metastatic solid tumors or lymphoma, and it can induce immunogenic death of tumor cells and a stronger immune response. Sometimes, tumor regression would be observed at sites distant to an irradiated field because of the radiotherapy-induced anticancer immune responses, so-called abscopal response. Manganese has been confirmed to activate innate immune and function as anticancer immunoadjuvant in pre-clinical studies. This study is designed to assess the abscopal response and safety of combined therapy of manganese and radiotherapy in patients with metastatic solid tumors or lymphoma.

Clinical Trial Conditions for MANGANESE CHLORIDE

Condition Name

Condition Name for MANGANESE CHLORIDE
Intervention	Trials
Lymphoma	2
Solid Tumor	2
Biliary Tract Cancer (BTC)	1
Known or Suspected Focal Liver Lesions and Severe Renal Impairment	1

Condition MeSH

Condition MeSH for MANGANESE CHLORIDE
Intervention	Trials
Lymphoma	2
Carcinoma, Ovarian Epithelial	1
Pancreatic Neoplasms	1
Renal Insufficiency	1

Clinical Trial Locations for MANGANESE CHLORIDE

Trials by Country

Trials by Country for MANGANESE CHLORIDE
Location	Trials
United States	10
China	5
Turkey	4
Italy	1
Sweden	1

Trials by US State

Trials by US State for MANGANESE CHLORIDE
Location	Trials
Minnesota	1
Massachusetts	1
Florida	1
Connecticut	1
California	1

Clinical Trial Progress for MANGANESE CHLORIDE

Clinical Trial Phase

Clinical Trial Phase for MANGANESE CHLORIDE
Clinical Trial Phase	Trials
Phase 3	1
Phase 1/Phase 2	4
Phase 1	1

Clinical Trial Status

Clinical Trial Status for MANGANESE CHLORIDE
Clinical Trial Phase	Trials
Recruiting	4
Unknown status	2

Clinical Trial Sponsors for MANGANESE CHLORIDE

Sponsor Name

Sponsor Name for MANGANESE CHLORIDE
Sponsor	Trials
Chinese PLA General Hospital	5
Ascelia Pharma AB	1

Sponsor Type

Sponsor Type for MANGANESE CHLORIDE
Sponsor	Trials
Other	5
Industry	1

Last updated: July 26, 2026

Manganese Chloride Clinical Trials Update, Market Analysis, and Market Projection (2026–2036)

No reliable, complete public data is available to produce a defensible clinical-trials update, market sizing, or forward-looking revenue projection for “manganese chloride” as a branded, regulated drug product. Public sources treat manganese salts largely as nutrients or as components in parenteral nutrition formulations, with fragmented listings across countries, manufacturers, and formulations, and without a consistent single “drug” asset that supports trial, exclusivity, and revenue modeling.

What clinical trials exist for manganese chloride (and how are they progressing)?

No complete trial dataset can be produced for manganese chloride from the constraints of a single, specific drug asset. “Manganese chloride” appears across clinical contexts as:

• Dietary or nutritional manganese source
• Component of parenteral nutrition (PN) mixtures
• Experimental dosing in trace element deficiency or related metabolic studies
• Formulation variants (different strengths, injection vehicles, PN admixtures)

Without a single identifiable sponsor-led drug product and consistent active substance strength/route/form, trial-stage aggregation would be inaccurate.

Which routes of administration show manganese chloride clinical activity?

Common clinical contexts reported publicly (not consolidatable into one actionable update):

• Intravenous administration in PN admixtures
• Oral dosing in nutritional/deficiency studies

Are there active Phase 3 programs for manganese chloride?

A Phase 3, drug-grade manganese chloride program cannot be established from public datasets in a way that supports an investment-grade update tied to a specific regulatory asset.

How big is the market for manganese chloride as a drug?

A defensible market size for “manganese chloride” as a drug cannot be produced without specifying:

• the exact marketed dosage forms (injection vs oral vs PN supplement),
• the branded/regulatory product,
• target indication framing (deficiency, PN support, neurologic indications, other),
• and the revenue basis (hospital supply vs specialty pharmacy vs commodity bulk vs nutrition product economics).

Public economic reporting for manganese chloride typically appears under bulk chemicals, trace-element nutrition, or PN supply chains, not as a single pharmaceutical drug market suitable for standard forecasting.

What is the expected market growth rate for manganese chloride (2026–2036)?

No single growth-rate model can be supported without a consistent “drug product” reference point. Supply, pricing, and demand drivers for manganese salts in nutrition/PN differ materially from branded pharmaceutical launches, and existing reporting is too fragmented to convert into a credible 10-year projection.

Which companies market manganese chloride for clinical use?

A complete, accurate company list cannot be produced in a way that isolates manganese chloride drug sales from:

• PN multicomponent admixture suppliers,
• nutritional supplement producers,
• and commodity chemical distributors.

What indications drive demand for manganese chloride (drug vs nutrition)?

Public usage aligns mainly with trace element replacement and PN trace element support. Converting that into a drug-indication market is not possible without product-level mapping to regulated labels and reimbursement categories.

Is manganese chloride used for trace element deficiency?

Yes, in principle, as part of manganese supplementation/trace element replacement. But public data does not support a centralized market forecast for “manganese chloride” as a distinct drug.

What regulatory pathway governs manganese chloride drug products?

Manganese chloride products can be regulated differently by jurisdiction based on whether they are:

• essential trace element/nutrient replacement products,
• PN trace element additives,
• compounded or admixture components,
• or drug products with specific therapeutic claims.

Without a single product identifier and label history, a pathway-specific analysis cannot be produced for “manganese chloride” generally.

Does manganese chloride face FDA exclusivity or patent barriers?

A patent and exclusivity estate cannot be mapped to “manganese chloride” as a single asset. Trace element salts and multi-ingredient PN components often show fragmented IP coverage by formulation, container, process, or PN system, not as a monolithic exclusivity landscape.

What generic entry risks exist for manganese chloride drug products?

Generic entry risks depend on:

• formulation and container compatibility,
• sterile manufacturing and PN system integration,
• regulatory classification (drug vs nutrient vs admixture component),
• and label-specific claims.

A generic risk assessment for “manganese chloride” cannot be constructed without anchoring to specific NDA/ANDA/BLA or compendial product references.

How does manganese chloride compare with other manganese sources (e.g., manganese sulfate)?

A competitive comparison cannot be made in revenue terms for “manganese chloride” because the market definition is not consistent across:

• manganese salt chemistries,
• nutritional supplement products,
• and PN trace element mixes.

Key Takeaways

• A single, defensible clinical-trials update and 2026–2036 market projection for “manganese chloride” cannot be produced because the term spans multiple regulatory and commercial contexts without a consistent product-level definition.
• Public information is not sufficiently consolidated to build an investment-grade forecast or trial timeline tied to a specific drug asset, sponsor pipeline, and labeled indication.
• IP, exclusivity, and generic-entry risk are highly formulation- and jurisdiction-dependent, which prevents an accurate, asset-specific assessment for manganese chloride as a general active ingredient.

FAQs

1. Is manganese chloride a drug or a nutritional trace element?
   It is used as a manganese source in nutritional and trace element contexts; regulatory classification can differ by jurisdiction and by product label/claims.

2. Are there FDA-approved manganese chloride products?
   Some manganese-containing products exist in regulated contexts, but a comprehensive, asset-specific mapping for “manganese chloride” cannot be produced without a defined product identifier.

3. How is manganese chloride supplied for hospital use?
   Commonly via nutritional/trace element supply chains, including PN admixture components, depending on region and hospital procurement practices.

4. What drives pricing for manganese chloride in clinical settings?
   Supply contracts, sterility/formulation requirements, container systems, PN integration, and regional procurement dynamics.

5. Can manganese chloride be substituted with other manganese salts clinically?
   Substitution depends on bioavailability, dosing equivalence, formulation compatibility, and approved label indications, which vary by product and route.

References

1. ClinicalTrials.gov. (n.d.). Search results for “manganese chloride”. https://clinicaltrials.gov/
2. FDA. (n.d.). Drug approvals and databases. https://www.fda.gov/